Relationship between expressions of somatostatin receptors subtype 2 mRNA and estrogen and progesterone receptors in breast cancer

Chinese Medical Journal

Volumn 116, Issue 12, 2003, Pages 1850-1853

  Zeng, Xizhi ^a   Yao, Zhenxiang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast neoplasm; Estrogen receptor; Somatostatin receptor

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; STEROID RECEPTOR; SOMATOSTATIN RECEPTOR;

ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; BREAST HYPERTROPHY; CANCER HORMONE THERAPY; CANCER TISSUE; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OLIGONUCLEOTIDE PROBE; PROTEIN EXPRESSION; BREAST DISEASE; BREAST TUMOR; CHEMISTRY; GENETICS; METABOLISM;

BREAST DISEASES; BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER;

EID: 2342613544     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217: 143-152.
2. Schulz S, Schulz S, Schmitt J, et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998;4:2047-2052.
3. Evans AA, Crook T, Laws S, et al. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 1997;75:797-803.
4. Sharma K, Patel YC, Srikant C. Subtype specific induction of wild type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688-1696.
5. Sharma K, Srikant CB. Induction of wild-type p53, bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998; 76: 259-266.
6. Thangaraju M, Sharma K, Liu D, et al. Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Res 1999;59:1649-1654.
7. Zeng XZ, Yao ZX. Synergistic effect of somatostatin and tamoxifen on human breast cancer cells in vitro. Chin J Surg 2001;39:545-547.
8. Keri GY, Erchegyi J, Horvath A, et al. A tumor-selective somatostatin analog (TT232) with strong in vitro and vivo antitumor activity. Proc Natl Acad Sci U S A 1996; 93: 12513-12518.
9. Charland S, Boucher MJ, Houde M, et al. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001;142:121-128.
10. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451.
11. Foekens JA, Portengen H, van Putten WL, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 1989;49:7002-7009.
12. Xu Y, Berelowitz M, Bruno JF, et al. Characterization of the promoter region of the human somatostatin receptor subtype 2 gene and localization of sequences required for estrogen-responsiveness. Mol Cell Endocrinol 1998;139:71-77.